Search the Newsreel

Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP reminds investors of a securities class action filed against Regeneron Pharmaceuticals (NASDAQ: REGN). The lawsuit alleges that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, which ultimately failed to meet its primary endpoint. Investors …

Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30

Regeneron Pharmaceuticals (REGN) is projected to report Q2 2026 earnings of $10.26 per share on revenue of $3.82 billion on July 30, before market open. Analyst sentiment has declined, with EPS estimates dropping 5.4% over the past 30 days, reflecting concerns about profitability headwinds. …

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which …

Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts project that Regeneron (REGN) will report second-quarter earnings of $10.00 per share, a 22.4% decrease year-over-year, with revenues expected to increase by 4.5% to $3.84 billion. The consensus EPS estimate has seen a 0.3% upward revision in the last 30 days. …

14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC

Orbimed Advisors LLC recently acquired 14,700 shares of Regeneron Pharmaceuticals, Inc. (REGN) valued at approximately $11.36 million during the first quarter. This comes as other institutional investors have also adjusted their stakes in the biopharmaceutical company, which has seen varied analyst sentiment and is …

Renaissance Technologies LLC Has $51.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Renaissance Technologies LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 635.5% in the first quarter, now holding 66,802 shares valued at $51.61 million. This move is part of broader institutional investor activity, with several other hedge funds also adjusting their positions in …

3,883 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Lombard Odier Asset Management Switzerland SA

Lombard Odier Asset Management Switzerland SA recently acquired 3,883 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) for approximately $3 million. Regeneron reported strong quarterly results, exceeding expectations with $9.47 EPS and $3.61 billion in revenue, and analysts maintain a "Moderate Buy" rating with an average price …

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Family Manage LLC

Family Manage LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 305.8% during the first quarter, now owning 3,794 shares valued at $2.93 million. Other institutional investors also adjusted their holdings, and the company recently reported strong quarterly earnings of $9.47 EPS, surpassing …

Entropy Technologies LP Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Entropy Technologies LP significantly increased its stake in Regeneron Pharmaceuticals, Inc. (REGN) by 173.7% in the first quarter, now holding 2,753 shares valued at approximately $2.13 million. Despite a "Moderate Buy" consensus from analysts, several firms have recently lowered price targets and one downgraded …

Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals recently entered a collaboration with Telix Pharmaceuticals for radiopharmaceutical cancer therapies but also faces a class-action lawsuit concerning disclosures about its Fianlimab-Libtayo trial. This article explores how the lawsuit impacts Regeneron's investment narrative and risks, particularly concerning its oncology pipeline, while emphasizing …

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ: REGN) by selling 34.2% of its shares, now owning 75,462 shares valued at $58.3 million. Despite this, other institutional investors like Lockheed Martin and Robeco Institutional Asset Management B.V. …

Sei Investments Co. Buys 18,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sei Investments Co. increased its stake in Regeneron Pharmaceuticals, Inc. by 32.5% in the first quarter, now owning 75,000 shares valued at $57.95 million. Other institutional investors also adjusted their holdings, while analyst ratings provide a "Moderate Buy" consensus with an average target price …

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of September 14, 2026 Deadline

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase …

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Lido Advisors LLC

Lido Advisors LLC reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 12.5% in the first quarter, selling 1,678 shares. Despite this, other institutional investors increased their holdings, and 83.31% of the stock is owned by institutions. Analysts maintain a "Moderate Buy" rating for REGN …

Cannell & Spears LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Cannell & Spears LLC reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 22.9% in the first quarter, selling over 20,000 shares. Despite this, other institutions like Robeco Institutional Asset Management B.V. and National Pension Service significantly increased their holdings. Analysts maintain a "Moderate Buy" …

GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040

This article provides a detailed overview of Galmed Pharmaceuticals Ltd (GLMD), covering its current market trends, financial performance, and analyst ratings. It highlights the company's focus on developing therapeutics for liver diseases, particularly its flagship product Aramchol for NASH. Despite recent weak stock market …

AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020

Atea Pharmaceuticals Inc. (AVIR) closed at $4.73, down 0.42%, with a market cap of $378.53 million. TradingKey analysis indicates stable fundamentals, high growth potential, and a "fairly valued" status within the Biotechnology & Medical Research industry, despite a short-term trend expected to move downwards. …

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Telix Pharmaceuticals (ASX:TLX) recently reported positive clinical data, initiated a Phase 3 trial, and raised its FY26 revenue outlook to over US$1 billion. These developments signify strong progress in its radiopharmaceutical pipeline and validate its theranostic business model. The upgraded guidance reinforces the company's …

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and its executives. The lawsuit alleges that Regeneron misled investors about the success of its Phase III Fianlimab-Libtayo clinical trial, causing significant stock drops. Investors are …

Regeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short Term (REGN)

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

SueWallSt is alerting investors in Regeneron Pharmaceuticals, Inc. (REGN) about a securities class action lawsuit with a lead plaintiff deadline of September 14, 2026. The lawsuit alleges that Regeneron minimized risks associated with its Phase III Fianlimab-Libtayo study, leading to a significant stock price …

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit is on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026, alleging that the company made misleading statements that led …

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding the Phase I …

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

Robbins LLP is urging investors who lost money in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, to contact the firm regarding a class-action lawsuit. The lawsuit alleges that Regeneron misled investors about the viability of its Phase III …

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals (REGN) is set to announce its fiscal Q2 2026 earnings on July 30, with analysts expecting a 25.4% drop in quarterly profit from the previous year. Despite underperforming the S&P 500 and the healthcare sector ETF over the past year, the company …

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III …

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Regeneron Pharmaceuticals Inc. (REGN) stock fell 3.56% to $651.18 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also saw declines. The company's stock closed 20.70% below its 52-week high of $821.11, reached on January 9th.

Regeneron Pharmaceuticals (REGN) Could Be 19% Undervalued After Recent Pipeline Focus

Regeneron Pharmaceuticals (REGN) is under the spotlight due to a new collaboration with Telix Pharmaceuticals and recent class-action filings, yet the stock is considered 19% undervalued with a fair value estimate of $833.31 against its current price of $675.19. The company's broad pipeline in …

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Bernstein Liebhard LLP is reminding investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a securities fraud class action lawsuit with a deadline of September 14,

REGN Court Alert: Regeneron Investors Seeking to Recover

A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its executives for alleged securities fraud. The lawsuit claims Regeneron misled investors about the success of its Phase III Fianlimab-Libtayo clinical trial, leading to significant stock drops on April 29, …

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

Regeneron Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit after its stock dropped significantly following the announcement of failed Phase III clinical trial results for its drug combination, Fianlimab-Libtayo. The lawsuit alleges that Regeneron misled investors about the trial's success, causing a …

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Bernstein Liebhard LLP has announced a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements about its business, leading to …

Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary

Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with net product revenues up 34% year-over-year to $410.1M and total revenues reaching $660M, a 107% increase. The company raised its 2024 net product revenue guidance to $1,575M–$1,650M following positive Phase 3 study results for vutrisiran …

Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal

Telix Pharmaceuticals reported strong Q2 2026 revenue of US$247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30%. The company expects FY 2026 revenue to exceed US$1 billion and has increased its R&D spending guidance to accelerate late-stage programs. Telix also announced …

Telix Pharmaceuticals (TLX) Q2 2026 TU earnings summary

Telix Pharmaceuticals (TLX) reported Q2 2026 group revenue of US $247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30% YoY. The company reached FDA alignment for its ProstACT Global Phase 3 study and initiated a strategic collaboration with Regeneron, receiving a …

REGN Shareholder Alert: September 14, 2026 Lead Plaintiff

Levi & Korsinsky, LLP has filed a securities class action against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron minimized concerns regarding a Phase III Fianlimab-Libtayo Study, …